These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 31634816)
21. Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model. Imamura Y; Yanagihara K; Fukuda Y; Kaneko Y; Seki M; Izumikawa K; Miyazaki Y; Hirakata Y; Sawa T; Wiener-Kronish JP; Kohno S Eur Respir J; 2007 May; 29(5):965-8. PubMed ID: 17301098 [TBL] [Abstract][Full Text] [Related]
22. A Live Aguilera-Herce J; García-Quintanilla M; Romero-Flores R; McConnell MJ; Ramos-Morales F mSphere; 2019 Apr; 4(2):. PubMed ID: 30996108 [No Abstract] [Full Text] [Related]
23. Development of a Broadly Protective, Self-Adjuvanting Subunit Vaccine to Prevent Infections by Das S; Howlader DR; Zheng Q; Ratnakaram SSK; Whittier SK; Lu T; Keith JD; Picking WD; Birket SE; Picking WL Front Immunol; 2020; 11():583008. PubMed ID: 33281815 [TBL] [Abstract][Full Text] [Related]
24. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. Frank DW; Vallis A; Wiener-Kronish JP; Roy-Burman A; Spack EG; Mullaney BP; Megdoud M; Marks JD; Fritz R; Sawa T J Infect Dis; 2002 Jul; 186(1):64-73. PubMed ID: 12089663 [TBL] [Abstract][Full Text] [Related]
26. Vaccination of mice with hybrid protein containing Exotoxin S and PcrV with adjuvants alum and MPL protects Pseudomonas aeruginosa infections. Asadi Karam MR; Badmasti F; Ahmadi K; Habibi M Sci Rep; 2022 Jan; 12(1):1325. PubMed ID: 35079054 [TBL] [Abstract][Full Text] [Related]
27. Immunotherapy with IgY Antibodies toward Outer Membrane Protein F Protects Burned Mice against Norouzi F; Behrouz B; Ranjbar M; Mousavi Gargari SL J Immunol Res; 2020; 2020():7840631. PubMed ID: 32566689 [TBL] [Abstract][Full Text] [Related]
28. Passive immunization with anti- chimeric protein PilQ/PilA -DSL region IgY does not protect against mortality associated with Pseudomonas aeruginosa sepsis in a rabbit model. Zamani K; Irajian G; Zahedi Bialvaei A; Zahraei Salehi T; Khormali M; Vosough A; Masjedian Jazi F Mol Immunol; 2022 Jan; 141():258-264. PubMed ID: 34896925 [TBL] [Abstract][Full Text] [Related]
29. PcrV antibody-antibiotic combination improves survival in Pseudomonas aeruginosa-infected mice. Song Y; Baer M; Srinivasan R; Lima J; Yarranton G; Bebbington C; Lynch SV Eur J Clin Microbiol Infect Dis; 2012 Aug; 31(8):1837-45. PubMed ID: 22187351 [TBL] [Abstract][Full Text] [Related]
30. Production of an Antibody Fragment (scFv) Targeting PcrV Protein of Pseudomonas aeruginosa in Fed-Batch Cultivation Mode. Karam S; Raigani M; Hassani Afshar S; Talebkhan Y; Bayat E; Komijani S; Nematollahi L; Barkhordari F; Shafiee Ardestani M; Davami F Iran Biomed J; 2021 Nov; 25(6):390-8. PubMed ID: 34641643 [TBL] [Abstract][Full Text] [Related]
31. Evaluation of the immune responses following co-administration of PilQ and type b-flagellin from Pseudomonas aeruginosa in the burn mouse model. Bakht Azad S; Nikokar I; Faezi S; Rasooly S; Mahdavi M Microb Pathog; 2018 Oct; 123():426-432. PubMed ID: 30075242 [TBL] [Abstract][Full Text] [Related]
32. Protective efficacy of Pseudomonas aeruginosa type-A flagellin in the murine burn wound model of infection. Faezi S; Safarloo M; Amirmozafari N; Nikokar I; Siadat SD; Holder IA; Mahdavi M APMIS; 2014 Feb; 122(2):115-27. PubMed ID: 23758581 [TBL] [Abstract][Full Text] [Related]
34. Protective effect of DNA vaccine encoding pseudomonas exotoxin A and PcrV against acute pulmonary P. aeruginosa Infection. Jiang M; Yao J; Feng G PLoS One; 2014; 9(5):e96609. PubMed ID: 24788626 [TBL] [Abstract][Full Text] [Related]
35. An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Baer M; Sawa T; Flynn P; Luehrsen K; Martinez D; Wiener-Kronish JP; Yarranton G; Bebbington C Infect Immun; 2009 Mar; 77(3):1083-90. PubMed ID: 19103766 [TBL] [Abstract][Full Text] [Related]
36. Development of a multi-epitope vaccine candidate against Kalantari H; Habibi M; Ferdousi A; Asadi Karam MR; Mohammadian T J Biomol Struct Dyn; 2024 Aug; 42(12):6212-6227. PubMed ID: 37489041 [No Abstract] [Full Text] [Related]
37. Anti-PcrV titers in non-cystic fibrosis patients with Pseudomonas aeruginosa respiratory tract infection. Nagaoka K; Yamashita Y; Kimura H; Kimura H; Suzuki M; Fukumoto T; Hayasaka K; Yoshida M; Hara T; Maki H; Ohkawa T; Konno S Int J Infect Dis; 2019 Oct; 87():54-59. PubMed ID: 31419482 [TBL] [Abstract][Full Text] [Related]
38. Oligomerization of PcrV and LcrV, protective antigens of Pseudomonas aeruginosa and Yersinia pestis. Gébus C; Faudry E; Bohn YS; Elsen S; Attree I J Biol Chem; 2008 Aug; 283(35):23940-9. PubMed ID: 18583342 [TBL] [Abstract][Full Text] [Related]
39. A Bispecific Monoclonal Antibody Targeting Psl and PcrV Enhances Neutrophil-Mediated Killing of Long MB; Gilmour A; Kehl M; Tabor DE; Keller AE; Warrener P; Gopalakrishnan V; Rosengren S; Crichton ML; McIntosh E; Giam YH; Keir HR; Brailsford W; Hughes R; Belvisi MG; Sellman BR; DiGiandomenico A; Chalmers JD Am J Respir Crit Care Med; 2024 Jul; 210(1):35-46. PubMed ID: 38754132 [No Abstract] [Full Text] [Related]
40. Identification of Small Molecules Blocking the Sundin C; Saleeb M; Spjut S; Qin L; Elofsson M Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33406810 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]